CMV423

CMV423
Clinical data
Other names	CMV-423; RPR-111423
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-Chloro-3-(pyridin-3-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide;
CAS Number	186829-19-6 ;
PubChem CID	489128;
ChemSpider	428515;
UNII	PDX37M872C;
CompTox Dashboard (EPA)	DTXSID40333187 ;
Chemical and physical data
Formula	C14H14ClN3O
Molar mass	275.74 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(cnc1)c2c(c(c3n2CCCC3)C(=O)N)Cl;
	InChI InChI=1S/C14H14ClN3O/c15-12-11(14(16)19)10-5-1-2-7-18(10)13(12)9-4-3-6-17-8-9/h3-4,6,8H,1-2,5,7H2,(H2,16,19); Key:KNGXENHWYNLKBU-UHFFFAOYSA-N;

CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection^[1] and human herpesvirus 6 (HHV-6) infection.^[2]^[3] The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.^[2]

References

^ Snoeck R, Andrei G, Bodaghi B, Lagneaux L, Daelemans D, de Clercq E, et al. (September 2002). "2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections". Antiviral Research. 55 (3): 413–424. doi:10.1016/s0166-3542(02)00074-8. PMID 12206879.
^ ^a ^b "CMV 423". AdisInsight. Springer Nature Switzerland AG.
^ Aoki FY (2015). "45 - Antivirals against Herpes Viruses". In Bennett JE, Blaser MJ, Dolin R (eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (8th ed.). pp. 546–562. doi:10.1016/B978-1-4557-4801-3.00045-X. ISBN 978-1-4557-4801-3.

[1] Snoeck R, Andrei G, Bodaghi B, Lagneaux L, Daelemans D, de Clercq E, et al. (September 2002). "2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections". Antiviral Research. 55 (3): 413–424. doi:10.1016/s0166-3542(02)00074-8. PMID 12206879.

[adisinsight-2] "CMV 423". AdisInsight. Springer Nature Switzerland AG.

[3] Aoki FY (2015). "45 - Antivirals against Herpes Viruses". In Bennett JE, Blaser MJ, Dolin R (eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (8th ed.). pp. 546–562. doi:10.1016/B978-1-4557-4801-3.00045-X. ISBN 978-1-4557-4801-3.

[1]

[2]

[3]